242 related articles for article (PubMed ID: 17395127)
1. Physiologic principles underlying ion channelopathies.
Cannon SC
Neurotherapeutics; 2007 Apr; 4(2):174-83. PubMed ID: 17395127
[TBL] [Abstract][Full Text] [Related]
2. Channelopathies of skeletal muscle excitability.
Cannon SC
Compr Physiol; 2015 Apr; 5(2):761-90. PubMed ID: 25880512
[TBL] [Abstract][Full Text] [Related]
3. Channels active in the excitability of nerves and skeletal muscles across the neuromuscular junction: basic function and pathophysiology.
Goodman BE
Adv Physiol Educ; 2008 Jun; 32(2):127-35. PubMed ID: 18539851
[TBL] [Abstract][Full Text] [Related]
4. Voltage-sensor mutations in channelopathies of skeletal muscle.
Cannon SC
J Physiol; 2010 Jun; 588(Pt 11):1887-95. PubMed ID: 20156847
[TBL] [Abstract][Full Text] [Related]
5. Ion channel pharmacology.
Camerino DC; Tricarico D; Desaphy JF
Neurotherapeutics; 2007 Apr; 4(2):184-98. PubMed ID: 17395128
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial channelopathies in aging.
Pi Y; Goldenthal MJ; Marín-García J
J Mol Med (Berl); 2007 Sep; 85(9):937-51. PubMed ID: 17426949
[TBL] [Abstract][Full Text] [Related]
7. Neurological channelopathies.
Kullmann DM
Annu Rev Neurosci; 2010; 33():151-72. PubMed ID: 20331364
[TBL] [Abstract][Full Text] [Related]
8. Alternative paradigms for ion channelopathies: disorders of ion channel membrane trafficking and posttranslational modification.
Curran J; Mohler PJ
Annu Rev Physiol; 2015; 77():505-24. PubMed ID: 25293528
[TBL] [Abstract][Full Text] [Related]
9. Sodium channelopathies of skeletal muscle and brain.
Mantegazza M; Cestèle S; Catterall WA
Physiol Rev; 2021 Oct; 101(4):1633-1689. PubMed ID: 33769100
[TBL] [Abstract][Full Text] [Related]
10. Trafficking mechanisms underlying neuronal voltage-gated ion channel localization at the axon initial segment.
Vacher H; Trimmer JS
Epilepsia; 2012 Dec; 53 Suppl 9(Suppl 9):21-31. PubMed ID: 23216576
[TBL] [Abstract][Full Text] [Related]
11. Relevance of tissue specific subunit expression in channelopathies.
Seitter H; Koschak A
Neuropharmacology; 2018 Apr; 132():58-70. PubMed ID: 28669898
[TBL] [Abstract][Full Text] [Related]
12. Mutational consequences of aberrant ion channels in neurological disorders.
Kumar D; Ambasta RK; Kumar P
J Membr Biol; 2014 Nov; 247(11):1083-127. PubMed ID: 25119057
[TBL] [Abstract][Full Text] [Related]
13. Ion channel diseases of the central nervous system.
Li M; Lester HA
CNS Drug Rev; 2001; 7(2):214-40. PubMed ID: 11474425
[TBL] [Abstract][Full Text] [Related]
14. Human muscle voltage-gated ion channels and hereditary disease.
Jurkat-Rott K; Lehmann-Horn F
Curr Opin Pharmacol; 2001 Jun; 1(3):280-7. PubMed ID: 11712752
[TBL] [Abstract][Full Text] [Related]
15. Neurological channelopathies: diagnosis and therapy in the new millennium.
Davies NP; Hanna MG
Ann Med; 1999 Dec; 31(6):406-20. PubMed ID: 10680855
[TBL] [Abstract][Full Text] [Related]
16. Pathomechanisms in channelopathies of skeletal muscle and brain.
Cannon SC
Annu Rev Neurosci; 2006; 29():387-415. PubMed ID: 16776591
[TBL] [Abstract][Full Text] [Related]
17. Channelopathies linked to plasma membrane phosphoinositides.
Logothetis DE; Petrou VI; Adney SK; Mahajan R
Pflugers Arch; 2010 Jul; 460(2):321-41. PubMed ID: 20396900
[TBL] [Abstract][Full Text] [Related]
18. Disorders of membrane channels or channelopathies.
Celesia GG
Clin Neurophysiol; 2001 Jan; 112(1):2-18. PubMed ID: 11137655
[TBL] [Abstract][Full Text] [Related]
19. Neurological channelopathies: new insights into disease mechanisms and ion channel function.
Kullmann DM; Waxman SG
J Physiol; 2010 Jun; 588(Pt 11):1823-7. PubMed ID: 20375141
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of channelopathies: impact on diagnosis and treatment.
Avanzini G; Franceschetti S; Avoni P; Liguori R
Expert Rev Neurother; 2004 May; 4(3):519-39. PubMed ID: 15853547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
